[Enteral availability and therapeutic activity of proscillaridin-4'-methyl ether (author's transl)].
20 cardiac patients with the clinical and radiological signs of heart failure were treated alternately intravenously and orally with proscillaridin-4'-methyl ether in a 2-period change-over procedure. With medium rate full saturation a steady state was maintained under observation of electrocardiographic parameters. The maintenance dose was determined to be 1.00 mg intravenously and 1.71 mg orally. Thus, relative enteral availability was 60%. In 70% of patients cardiac recompensation could be reached only by treatment with proscillaridin-4'-methyl ether. In 9 of 20 patients undesirable side effects consisted of laxative effects.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001682:Biological Availability; D002018:Bufanolides / Q000008:administration & dosage*; D005260:Female; D006333:Heart Failure / Q000188:drug therapy*; D006339:Heart Rate; D006801:Humans; D007275:Injections, Intravenous; D007408:Intestinal Absorption; D008297:Male; D008875:Middle Aged; D011442:Proscillaridin / Q000008:administration & dosage* / Q000031:analogs & derivatives / Q000378:metabolism
D002018:Bufanolides; D011442:Proscillaridin
Enterale Verfügbarkeit und therapeutische Wirksamkeit von Proscillaridin-4' methyläther